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There is uncertainty about the development of airway tolerance to b-agonists and the phenomenon of rebound
bronchoconstriction on b-agonist withdrawal. We have recently completed a study of the regular terbutaline and
budesonide treatment in asthma. We report our observations on the eect of starting and stopping terbutaline
treatment on morning and evening peak flows.
The study was a randomized four-way, double-dummy, cross-over comparison of regular inhaled terbutaline
(500–1000 mg four times daily), budesonide, combined treatment and matching placebo. Each treatment was given
for 6 weeks following a 4 week single-blind placebo washout. Ipratropium was used for symptom relief. No other
asthma medication was permitted during either the treatment or wash-out periods. Evaluable data were obtained
from 52 subjects for both placebo and terbutaline treatment. Changes in mean morning and evening peak flows
during terbutaline treatment were compared to the baseline peak flows during the last 2 weeks of the preceding
washout. The peak flow changes on stopping terbutaline were also analysed.
Mean morning peak flow was not significantly dierent during terbutaline treatment when compared to either
baseline or placebo treatment. Evening peak flows were significantly higher during terbutaline treatment [mean
increase 23?1 lmin71 (95%CI=18?8, 27?4)]. Analysis of the peak flow changes on a day-by-day basis revealed an
initial increase in morning peak flows for the first 2 days of treatment of 19?2 and 13?4 lmin71 [increases of 25?0 and
17?3 lmin71 in comparison with the corresponding values during placebo (P50?01)] followed by a return to
baseline. The increase in evening peak flows was also greater for the first 2 days of treatment than for the remainder
of the treatment period (P50?01). On ceasing terbutaline treatment there was a fall in mean morning peak flow
below the baseline on the following morning of 21?6 lmin71 (P50?05 compared to placebo).
The temporary increase in morning peak flows and greater than expected rise in evening peak flows for the first 2
days of treatment suggest the development of tolerance to the bronchodilator eect of terbutaline. Similarly, the fall
in morning peak flows on treatment withdrawal suggests rebound bronchoconstriction. These eects are likely to be
mediated by downregulation of the b-receptor during treatment. The clinical significance of these changes is
uncertain in view of the stability of overall asthma control during terbutaline treatment, but sudden withdrawal of
b-agonist treatment could conceivably lead to a deterioration in asthma control.
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b-receptors during b2-agonist treatment in asthma is
uncertain. Early reports indicated that significant tolerance
to their bronchodilator eects does not occur (2). More
recent studies have demonstrated a small reduction in the
bronchodilator eect during treatment with long-acting
b-agonist (3–5). Regular use of b-agonist has also
been shown to lead to a reduction in functional antagonism
to constricting stimuli (6) and a reduced bronchodi-
lator response to b-agonist during acute bronchoconstric-
tion (7).# 2000 HARCOURT PUBLISHERS LTD
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the phenomenon of rebound bronchoconstriction on
treatment withdrawal (8–10). Whether this withdrawal
eect has clinical significance is unclear, but in some
circumstances it could conceivably contribute to an acute
deterioration in asthma control in patients with brittle
asthma.
We have recently reported a study of terbutaline and
budesonide treatment designed to examine the interaction
between these drugs (11). The data obtained also allowed us
to analyse the eects of starting and stopping terbutaline
treatment. Our observations are reported here.
Methods
The study design has been reported elsewhere (11). In brief,
volunteers aged 9–64 with mild to moderate atopic asthma
and bronchial hyperresponsiveness to methacholine
(PC208mgml71) were recruited. Subjects on high dose
inhaled corticosteroids (41500mg day71 in adults,
4800 mg day71 in children aged513 years of age), oral
steroids and current or ex-cigarette smokers (45 pack
years) were excluded. The study was approved by the Otago
Ethics Committee. Each subject (or their parent/guardian)
gave written informed consent.
The study was a double-blind, random-order, double-
dummy, cross-over comparison of four treatments: terbuta-
line 1000 mg four times daily, budesonide 400 mg twice daily,
both drugs and placebo. Doses were halved for children
under 13 years. Each treatment was given for 6 weeks.
Inhaled corticosteroid treatment was withdrawn for at least
2 weeks before starting a 4 week single-blind placebo run-in
during which no asthma treatment was used other than
inhaled ipratropium bromide as required for symptom
relief. Identical 4-week single blind washouts were used
between each treatment. Subjects continued to use inhaled
ipratorpium bromide for symptom relief throughout the
study. No other asthma treatment was permitted except inTABLE 1. Eect of 6 weeks regular treatment with regular terb
Placebo (95% CI)
Morning peak flow 415 (390, 440)
D Morning peak flow* 0?7 (73?6, 5?0)
Evening peak flow 423 (399, 447)
D Evening peak flow* 70?7 (74?8, 3?4)
FEV1 2?91 (2?83, 2?99)
D FEV1
{ 70?067 (70?14, 0?0
FVC 3?76 (3?66, 3?85)
D FVC{ 70?061 (70?15, 0?0
Geometric mean PD20 0?524 (0?40, 0?68)
D PD20 change
{{ 0?024 (70?31, 0?3
*Change from baseline (mean peak flows during last 2 week
immediately before starting placebo or terbutaline treatment; {
CI: confidence interval; FEV1: Forced expiratory volume in 1
causing a 20% fall in FEV1.the event of an exacerbation in which case the subject was
withdrawn from the treatment period. Subjects kept a
record of peak flows measured before the morning and
evening doses of study inhalers. Spirometry and methacho-
line challenge tests were performed at the beginning and
end of each treatment.
This analysis was a post hoc study of changes in morning
and evening peak flow during terbutaline treatment. The
mean changes in morning and evening peak flows were
calculated for each day and each week of the treatment
periods and washout intervals. The mean peak flows for the
2 weeks immediately prior to starting treatment, during
which subjects were receiving single-blind placebo treat-
ment, were used as the baseline for evaluating subsequent
changes. Where data were available, the changes in peak
flows on stopping treatment were also calculated. Unfortu-
nately washout data were not collected following the last of
the four treatment periods, hence these data are only
available for approximately 75% of subjects. Changes from
baseline on starting and stopping terbutaline were com-
pared to the equivalent days on placebo using a one-way
analysis of variance.
Results
Fifty-five subjects received terbutaline and 54 received
placebo. One subject withdrew during terbutaline treatment
because of tremor and had insucient data for analysis.
Two subjects were excluded from analysis because of
irregularities with their peak flow recording. Thus data
were analysed for 52 subjects taking each treatment. The
mean values for lung function data obtained during each
treatment period are shown in the Table 1.
Over the 6 weeks of regular treatment terbutaline did not
significantly alter mean morning peak flow with respect to
either baseline or placebo [mean (95% CI) increase from
baseline 2?5 (71?8, 6?8) lmin71). However, analysis of the
daily peak flow changes showed a mean (95% CI) increaseutaline on lung function and bronchial hyperresponsiveness
Terbutaline (95% CI) P-value
417 (392, 442) 0?53
2?5 (71?8, 6?8) 0?47
447 (423, 470) 0?0001
23?1 (18?8, 27?4) 0?0001
2?90 (2?81, 2?99) 0?87
1) 70?083 (70?17, 0) 0?78
3?74 (3?64, 3?84) 0?81
3) 70?094 (70?19, 0) 0?64
0?637 (0?48, 0?85) 0?38
5) 0?094 (70?29, 0?47) 0?84
s of each run-in period); {Change from the value measured
DPD20 is expressed as doubling dose changes.
sec; FVC: Forced vital capacity, PD20: provocational dose
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baseline for the first two mornings of terbutaline treatment
followed by a return to baseline by day 3 (Fig. 1). When
compared to the corresponding days during placebo the
mean peak flows were 25?0 and 17?3 lmin71 higher during
terbutaline (P50?002 and P50?01, respectively).
On withdrawal of terbutaline there was a fall of 21?6 (4?1,
39?1) lmin71 below baseline on the first morning after
stopping treatment. This was significantly lower than
placebo [mean dierence between terbutaline and placebo
of 23?1 lmin71 (P=0?024)]. Peak flows on the second
morning after stopping terbutaline were not significantly
dierent from placebo and returned to baseline by day 3
(Fig. 1).
Evening peak flows were significantly higher during
terbutaline treatment than during the baseline or placebo.
The mean (95% CI) increase from baseline was 23?1 (18?8,
27?4) lmin71 (P50?0001). The increases in evening
peak flows on the first and second days of terbutaline
treatment were significantly greater than this mean change
[mean (95% CI) increase 32?7 (19?5, 45?9) and 35?4 (24?1,
46?7) lmin71 respectively; P=0?014 and P50?0002]
(Fig. 2).
After terbutaline was discontinued there was a small fall
in evening peak flows below baseline [mean (95% CI)FIG. 1. Time trends in (a) morning and (b) evening peak flows b
CI) changes from baseline are shown for each day of the weeks
of the treatment period, and for each day of the weeks before
treatment period are indicated by the broken line. The baseline
of the pre-treatment washouts.8?3 lmin71]. This was not significantly lower than the
baseline but was of borderline significance compared to
placebo (mean dierence between placebo and terbutaline
of 22?5 lmin71, P=0?055) (Fig. 1).
Discussion
The observations reported here were not based on an a
priori hypothesis and require cautious interpretation.
However, they strongly suggest the development of
tolerance to the bronchodilator eect of terbutaline
occurring within 2 days of starting treatment and that
rebound bronchoconstriction occurred for a similar interval
when terbutaline was withdrawn.
The increase in morning peak flows observed on starting
terbutaline treatment was unexpected since morning peak
flows were measured before the first daily dose of terbuta-
line. However, this would be consistent with the evening
doses having had a prolonged bronchodilator eect for the
first 2 days of treatment, followed by the development of
tachyphylaxis to its duration of action by the third day.
Shortening of the duration of the bronchodilator action of
b-agonists has been described previously, although the time
course for this eect has not (12–15).efore, during and after terbutaline treatment. Mean (+95%
before (run-in) and after starting terbutaline, for the 6 weeks
and after stopping treatment. Mean changes of the placebo
was defined as the mean peak flow of the last 2 weeks of each
770 R. J. HANCOX ET AL.Evening peak flows were measured before the final daily
dose of study medication — typically 4–5 h after the
afternoon dose. The finding that the increase in mean peak
flow was greater for the first two evenings of terbutaline
than during the remainder of the treatment period suggests
that this may also have been aected by tachyphylaxis. A
similar eect was noted in a study of the long-acting
b-agonist, formoterol, in which there was a reduced
increase in peak flows after 2 days of treatment (16).
However, in that study, the use of a long-acting b-agonist
meant that this eect was observed in morning peak flows
which were measured after a longer (overnight) interval
after administration of the previous dose.
The fall in mean peak flow below baseline on the first
morning after stopping terbutaline treatment suggests
rebound bronchoconstriction. This is consistent with
previous findings (8–10). The eect was not caused by the
methacholine challenge procedure at the clinic visit since it
was not observed at the time of stopping placebo treatment.
However, the use of salbutamol after the methacholine
challenge may have masked a rebound fall in evening peak
flow on the day of terbutaline withdrawal. Thus the mean
evening peak flow did not fall significantly below baseline
on this day, but did appear to be reduced compared to
placebo (P=0?055).
The timing of these changes is consistent with evidence
that downregulation of b2-receptors on bronchial epithelial
cells and alveolar macrophages occurs after 24 h of regular
inhaled b-agonist treatment (17). Our data suggest that
spontaneous recovery of b2-receptor function in bronchial
smooth muscle occurs over a similar period.
The eects of regular terbutaline on overall asthma
control, spirometry, bronchial hyperresponsiveness to
methacholine and morning peak flows in this study have
previously been reported (11). There was no evidence that
terbutaline had an adverse eect on any of these outcomes
over the 6 week study period (Table 1). However, the
observations reported here suggest that terbutaline treat-
ment leads to significant downregulation of airway b-
receptors. The clinical significance is uncertain in view of
the overall stability of asthma control during terbutaline.
The magnitude of the mean peak flow changes reported
here is not large (approximately 20 lmin71) and recovery of
b-receptor function appears to be rapid. Despite this it is
possible that loss of b-receptor function during regular b-
agonist treatment contributes to an acute deterioration in
asthma control if treatment is stopped abruptly in some
patients. We have demonstrated that patients may fail to
respond adequately to bronchodilator as a result of regular
b-agonist use (17). A combination of these factors may
partly explain the association between frequent use of b-
agonists with asthma mortality (18,19).
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